Prognosis
Carcinogen in Zantac and Generics Triggers FDA, EU Probes
- Inquiries follow discovery last year of NDMA in heart drugs
- FDA doesn’t see immediate health risk, plans further study
This article is for subscribers only.
Global health regulators sounded a coordinated alarm about the possibility that a stomach drug taken by millions of people could be tainted with the same cancer-causing agent that has sparked a worldwide recall of blood-pressure pills.
Drug-safety officials in the U.S. and Europe said Friday that they were looking into whether Sanofi heartburn medication Zantac and generic versions made by numerous manufacturers contain levels of the probable carcinogen NDMA that could pose a danger to patients.